BiotechTube
BioSpring

BioSpring

Frankfurt, Germany· Est.
biospring.net
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioSpring is a long-established, privately-held CDMO focused exclusively on nucleic acid manufacturing and analytics. With nearly three decades of experience and GMP certification since 2007, it offers end-to-end solutions for a wide range of oligonucleotide modalities, including ASOs, siRNA, mRNA, and guide RNA. The company supports hundreds of clinical trials and nine commercial programs, leveraging its expertise in process development, scalable production, and regulatory documentation to advance client therapies from bench to bedside.

Synthetic BiologyBiologics

Technology Platform

Integrated platform for the chemical synthesis, purification, and analytical characterization of diverse nucleic acid modalities (ASO, siRNA, mRNA, gRNA, XNA, etc.) across all GMP grades, from preclinical to commercial scale.

Opportunities

The rapid expansion of the nucleic acid therapeutics pipeline, driven by modalities like mRNA and siRNA, creates sustained demand for specialized CDMO services.
BioSpring's established track record and GMP expertise position it to capture a significant share of this growing outsourced market, particularly for complex molecules and commercial-scale supply.

Risk Factors

Key risks include intensifying competition from larger CDMOs and new entrants, reliance on the clinical and commercial success of client programs, and the ever-present operational risk of a quality failure or regulatory issue at its GMP facilities, which could severely damage its reputation.

Competitive Landscape

BioSpring competes in the specialized nucleic acid CDMO space against other pure-play firms (e.g., Axolabs, LGC Biosearch Technologies) and the expanding oligonucleotide/mRNA service divisions of large, diversified CDMOs like Lonza, Catalent, and Thermo Fisher Scientific. Its deep, focused expertise and long history are its primary differentiators.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →